Selective Targeting of Cancer Cells by Copper Ionophores: An Overview.
ROS
anticancer
chemotherapeutics
copper ionophores
cuproplasia
cuproptosis
prodrug
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
12
2021
accepted:
09
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Conventional cancer therapies suffer from severe off-target effects because most of them target critical facets of cells that are generally shared by all rapidly proliferating cells. The development of new therapeutic agents should aim to increase selectivity and therefore reduce side effects. In addition, these agents should overcome cancer cell resistance and target cancer stem cells. Some copper ionophores have shown promise in this direction thanks to an intrinsic selectivity in preferentially inducing cuproptosis of cancer cells compared to normal cells. Here, Cu ionophores are discussed with a focus on selectivity towards cancer cells and on the mechanisms responsible for this selectivity. The proposed strategies, to further improve the targeting of cancer cells by copper ionophores, are also reported.
Identifiants
pubmed: 35309510
doi: 10.3389/fmolb.2022.841814
pii: 841814
pmc: PMC8931543
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
841814Informations de copyright
Copyright © 2022 Oliveri.
Déclaration de conflit d'intérêts
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor and reviewers QD and XC declared their involvement as co-editors in the Research Topic, and confirm the absence of any other collaboration.
Références
J Cancer Res Clin Oncol. 2017 Sep;143(9):1789-1809
pubmed: 28647857
Eur J Med Chem. 2020 Dec 1;207:112670
pubmed: 32858470
Recent Pat Anticancer Drug Discov. 2019;14(2):113-132
pubmed: 31084595
Biomaterials. 2013 Oct;34(31):7662-73
pubmed: 23859657
Biochim Biophys Acta Mol Cell Res. 2021 Feb;1868(2):118893
pubmed: 33091507
Angew Chem Int Ed Engl. 2016 Feb 12;55(7):2550-4
pubmed: 26749149
Biochem J. 2011 Jun 1;436(2):481-91
pubmed: 21426304
Angew Chem Int Ed Engl. 2019 Jan 21;58(4):946-956
pubmed: 30048028
Angew Chem Int Ed Engl. 2018 Sep 24;57(39):12780-12784
pubmed: 30025197
Biochim Biophys Acta. 2013 Apr;1835(2):164-9
pubmed: 23266512
J Surg Oncol. 1993 Mar;52(3):172-5
pubmed: 8441275
Pharmaceutics. 2020 May 20;12(5):
pubmed: 32443790
Free Radic Biol Med. 2017 Jul;108:554-563
pubmed: 28431962
Oncotarget. 2016 Sep 6;7(36):58516-58530
pubmed: 27542268
Cancers (Basel). 2009;1(1):23-38
pubmed: 20535236
Biomed Pharmacother. 2018 Mar;99:561-569
pubmed: 29902866
PLoS One. 2018 Sep 13;13(9):e0203069
pubmed: 30212479
J Clin Diagn Res. 2015 Jan;9(1):BC25-c27
pubmed: 25737978
Nat Chem Biol. 2019 Jul;15(7):681-689
pubmed: 31133756
Biochem Pharmacol. 2015 Feb 1;93(3):266-76
pubmed: 25550273
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41118-41128
pubmed: 30444340
Cancers (Basel). 2020 Dec 01;12(12):
pubmed: 33271772
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19507-12
pubmed: 24218578
Gynecol Oncol. 2018 Dec;151(3):422-427
pubmed: 30309721
ChemistryOpen. 2015 Jul 14;4(6):792-5
pubmed: 27308206
Carcinogenesis. 2017 Jul 1;38(7):699-707
pubmed: 28575311
Free Radic Biol Med. 2012 May 15;52(10):2142-50
pubmed: 22542443
Nat Rev Cancer. 2022 Feb;22(2):102-113
pubmed: 34764459
Biochem J. 2009 Jan 1;417(1):133-9
pubmed: 18764784
Appl Mater Today. 2020 Mar;18:
pubmed: 34746366
Mol Oncol. 2015 Jun;9(6):1155-68
pubmed: 25769405
Sci Rep. 2014 Jul 18;4:5749
pubmed: 25034786
Nat Commun. 2020 Jul 24;11(1):3701
pubmed: 32709883
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
World J Surg. 2013 Nov;37(11):2641-6
pubmed: 23942528
Free Radic Biol Med. 2020 Apr;150:1-11
pubmed: 32032663
Toxicol Lett. 2008 Nov 10;182(1-3):1-6
pubmed: 18812216
J Inorg Biochem. 2016 Sep;162:31-43
pubmed: 27297691
Front Mol Biosci. 2021 Aug 24;8:711227
pubmed: 34504870
Angew Chem Int Ed Engl. 2020 Dec 7;59(50):22537-22543
pubmed: 32856362
Nature. 2017 Dec 14;552(7684):194-199
pubmed: 29211715
Biol Trace Elem Res. 2017 Jan;175(1):57-64
pubmed: 27263537
Cancer Res. 2006 Nov 1;66(21):10425-33
pubmed: 17079463
Oncotarget. 2012 Oct;3(10):1124-36
pubmed: 23165409
Clin Cancer Res. 2013 Aug 15;19(16):4309-14
pubmed: 23719265
Cell Death Dis. 2017 May 18;8(5):e2797
pubmed: 28518151
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Free Radic Biol Med. 2020 May 20;152:597-608
pubmed: 31805398
Carbohydr Res. 2020 Dec;498:108195
pubmed: 33220603
PLoS One. 2021 Nov 3;16(11):e0251957
pubmed: 34731160
Adv Cancer Res. 2014;122:103-41
pubmed: 24974180
Biomedicines. 2021 Jul 21;9(8):
pubmed: 34440056
J Med Chem. 2004 Dec 30;47(27):6914-20
pubmed: 15615540
Br J Cancer. 2011 May 10;104(10):1564-74
pubmed: 21487404
Dalton Trans. 2016 Jul 19;45(29):11830-8
pubmed: 27373800
J Control Release. 2015 Apr 10;203:126-39
pubmed: 25701309
Biochemistry. 2002 Mar 5;41(9):2990-7
pubmed: 11863437
ACS Chem Biol. 2013 Jul 19;8(7):1621-31
pubmed: 23656859
J Clin Oncol. 2009 Nov 10;27(32):5452-8
pubmed: 19826135
Free Radic Biol Med. 2018 Aug 20;124:342-352
pubmed: 29935260
Metallomics. 2015 Nov;7(11):1459-76
pubmed: 26313539
Dalton Trans. 2011 Feb 14;40(6):1338-47
pubmed: 21173986
J Inorg Biochem. 2014 Aug;137:22-30
pubmed: 24798374
Free Radic Biol Med. 2018 May 20;120:124-132
pubmed: 29555591
Free Radic Biol Med. 2018 Dec;129:215-226
pubmed: 30240704
J Am Chem Soc. 2016 Sep 28;138(38):12541-51
pubmed: 27570149
Biomed Pharmacother. 2019 Dec;120:109529
pubmed: 31606620
Environ Sci Pollut Res Int. 2015 May;22(10):7930-5
pubmed: 25520207
Cancer Res. 2014 Oct 15;74(20):5819-31
pubmed: 25320179
J Int Med Res. 2018 Dec;46(12):4863-4873
pubmed: 30296873
Cell Commun Signal. 2020 Mar 5;18(1):36
pubmed: 32138738
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127148
pubmed: 32253061
Acta Biomater. 2018 Mar 1;68:113-124
pubmed: 29294377
J Am Chem Soc. 2018 Oct 24;140(42):13764-13774
pubmed: 30351140
Inorg Chem. 2019 Oct 21;58(20):13528-13545
pubmed: 31247859
Adv Drug Deliv Rev. 2017 Sep 1;118:65-77
pubmed: 28676386
Cancers (Basel). 2020 Jan 06;12(1):
pubmed: 31935835
J Control Release. 2020 Mar 10;319:352-359
pubmed: 31911155
Oncotarget. 2016 Jun 14;7(24):37064-37080
pubmed: 27175597
Drug Discov Today. 2020 Jun;25(6):1099-1108
pubmed: 32320854
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):47-52
pubmed: 22173633
Cancer Lett. 2011 Dec 15;312(1):11-7
pubmed: 21899946
Mol Cell Endocrinol. 2017 Dec 5;457:57-72
pubmed: 27773847
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:206-213
pubmed: 27987700
ChemMedChem. 2021 Aug 5;16(15):2315-2329
pubmed: 33890721
Indian J Med Sci. 1994 Oct;48(10):227-32
pubmed: 7829172
Curr Urol. 2020 Mar;14(1):44-49
pubmed: 32398996
ACS Appl Mater Interfaces. 2018 Oct 3;10(39):33010-33021
pubmed: 30209950
Oral Dis. 2019 Jan;25(1):80-86
pubmed: 30107072
Drug Deliv Transl Res. 2018 Feb;8(1):239-251
pubmed: 29247315
Chem Soc Rev. 2020 Jun 22;49(12):3726-3747
pubmed: 32525153
Breast Cancer Res. 2005;7(6):R897-908
pubmed: 16280039
Metallomics. 2020 Dec 23;12(12):1979-1994
pubmed: 33169753
Cancer Metastasis Rev. 2019 Sep;38(3):333-346
pubmed: 31659564
Front Mol Biosci. 2021 Sep 17;8:741316
pubmed: 34604310
Int J Pharm. 2021 Sep 25;607:120972
pubmed: 34363916
IUBMB Life. 2020 Sep;72(9):1900-1908
pubmed: 32599675
J Clin Exp Hepatol. 2017 Jun;7(2):152-154
pubmed: 28663680
Chem Commun (Camb). 2019 Nov 14;55(92):13896-13899
pubmed: 31675022
J Am Chem Soc. 2019 Jul 24;141(29):11531-11539
pubmed: 31251050